877265-10-6

Usage

Uses

Used in Pharmaceutical Industry:
7-bromo-2-methyl-1,2-dihydroisoquinolin-3(4H)-one is used as a building block for the synthesis of complex organic molecules, which can be further developed into new drugs with specific therapeutic properties. Its unique structure allows for the exploration of various pharmacological activities, making it a promising candidate for drug discovery and development.
Used in Medicinal Chemistry Research:
7-bromo-2-methyl-1,2-dihydroisoquinolin-3(4H)-one is used as a valuable compound in medicinal chemistry research. Its structural properties enable the investigation of its potential biological activities and its role in the development of new drugs. 7-broMo-2-Methyl-1,2-dihydroisoquinolin-3(4H)-one can be modified and studied to understand its interactions with biological targets, contributing to the advancement of pharmaceutical science.

InChI:InChI=1/C10H10BrNO/c1-12-6-8-4-9(11)3-2-7(8)5-10(12)13/h2-4H,5-6H2,1H3

Upstream product

• 50-00-0 formaldehyd 
• 7713-76-0 2-(4-bromophenyl)-N-methylethanamide 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 37859-24-8 2-(4-bromophenyl)acetyl chloride 

Downstream Products

• 1425926-97-1 N-(2-methyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)benzene-sulfonamide 

Relevant academic research and scientific papers

A Series of Analogues to the AT2R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode

We here report on our continued studies of ligands binding to the promising drug target angiotensin II type 2 receptor (AT2R). Two series of compounds were synthesized and investigated. The first series explored the effects of adding small subs

Initial process development and scale-up of the synthesis of a triple reuptake inhibitor ALB 109780

Early process development toward a triple reuptake inhibitor is described. Three different routes were evaluated; one of them was optimized and scaled up to generate 470 g of API as this route minimized the formation of undesired side products. The select

Process development and pilot-scale synthesis of new cyclization conditions of substituted phenylacetamides to tetrahydroisoquinoline-2-ones using Eaton's reagent

Tetrahydroisoquinoline is a ubiquitous structural framework presented in numerous pharmacologically relevant molecules. Although accessible by the Pictet-Spengler cyclization, conditions commonly used for such cyclizations are often difficult to implement on scale. Herein, we report the development of a scaleable approach utilizing Eaton's reagent for the cyclization of substituted phenylacetamide analogues to tetrahydroisoquinoline-2-one. The development, optimization, and safety hazard evaluations, which outline the benefits and ease of workup of this new process, are discussed.